AlphaStocks

CRL vs FTI

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. vs TechnipFMC plc — Side-by-Side Stock Comparison

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

4.5

Weak

$175.16

FTI

TechnipFMC plc

8.5

Strong Buy

$69.81

CRL vs FTI: Which is the Better Investment?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) scores 4.5/10 while TechnipFMC plc (FTI) scores 8.5/10 on AlphaStocks' composite model. TechnipFMC plc has the higher composite rating of Strong Buy.

This comparison is algorithmically generated and is not financial advice.

MetricCRLFTI
Scores & Fundamentals
Composite Score4.5/108.5/10
RatingWeakStrong Buy
Price$175.16$69.81
P/E Ratio30.4
ROE-4.4%28.8%
Market Cap$9B$29B
Fair Value$113.84$48.94
Dividend Yield
Sector Rank#704 of 1127#2 of 1127
Model Verdicts
PiotroskiAttractiveStrong
BuffettNeutralStrong
GrahamCautionCaution
LynchAttractiveStrong
GreenblattNeutralNeutral
View full CRLanalysis →View full FTIanalysis →
Compare any two stocks →

CRL vs FTI: Which Stock Scores Higher?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) and TechnipFMC plc (FTI) are among the most compared stocks in the S&P 500. FTI currently leads with a composite score of 8.5/10 (Strong Buy) compared to CRL's 4.5/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer